Last Update: May 09, 2012
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
| |
Non-linear mixed effects modeling of antiretroviral drug response
after administration of lopinavir, atazanavir
and efavirenz
containing regimens to treatment-naďve HIV-1 infected patients.
Röshammar D, Simonsson US, Ekvall H,
et al
J Pharmacokinet Pharmacodyn.
2011 Oct 2.
Abstract
Synthesis and antimycobacterial activity of novel amino
alcohols containing central core of the
anti-HIV drugs Lopinavir and Ritonavir.
Gomes CR, Moreth M, Cardinot D, et al
Chem Biol Drug Des.
2011 Sep 20.
Abstract
Lopinavir up-regulates expression of the antiviral
protein ribonuclease L in
human papillomavirus-positive cervical carcinoma cells.
Batman G, Oliver AW, Zehbe I,
et al
Antivir Ther.
2011;16(4):515-25.
Abstract
Effect of boosted fosamprenavir or lopinavir-based combinations on
whole-body insulin
sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Randell PA, Jackson AG, Boffito M, et al
Antivir Ther.
2010;15(8):1125-1132
Abstract |
Differential Effects of Efavirenz and Lopinavir/Ritonavir on Human Adipocyte
Differentiation,
Gene Expression and Release of Adipokines and Pro-Inflammatory Cytokines.
Gallego-Escuredo1 JM, Del Mar Gutierrez M, Diaz-Delfin J, et al
Curr HIV Res. 2010 Oct 1;
Abstract |
Lopinavir Loaded Solid Lipid Nanoparticles (SLN) for Intestinal
Lymphatic Targeting
Alex MR, Chacko AJ,
Jose S, Souto EB.
Eur J Pharm Sci. 2010
Oct 21.
Abstract |
Lopinavir inhibits meningioma cell proliferation by Akt
independent mechanism.
Johnson MD, O'Connell M, Pilcher W.
J Neurooncol.
2010 Jul 2.
Abstract |
A WEEK-IN-REVIEW FEATURED
REPORT
Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers,
but
poor substrates, of ABC transporters in a broad panel of ABC transporter-
overexpressing cell lines.
Bierman WF, Scheffer GL,
Schoonderwoerd A, et al
J Antimicrob Chemother.
2010 Jun 15
Abstract |
Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the
Initial Viral Decay
Rate in Treatment Naďve HIV-1-Infected Patients.
Edén A, Andersson LM, Andersson O, et al
AIDS Res Hum Retroviruses.
2010 May 10.
Abstract |
Combining metabolic fingerprinting and footprinting to understand the
phenotypic response
of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral
drug lopinavir.
Kim DH, Jarvis RM, Xu Y,
et al
Analyst. 2010 Apr 14.
Abstract |
A WEEK-IN REVIEW FEATURED REPORT
The impact of SLCO1B1 polymorphisms on the plasma concentration
of lopinavir
and ritonavir in HIV-infected men.
Kohlrausch FB, de Cássia Estrela R, Barroso PF, Suarez-Kurtz G.
Br J Clin Pharmacol.
2010 Jan;69(1):95-98
Abstract |
Lopinavir Cerebrospinal Fluid Steady-State Trough Concentrations in
HIV-Infected Adults
(December).
Dicenzo R,
Difrancesco R, Cruttenden K, et al
Ann Pharmacother.
2009 Nov 24
Abstract |
Plasma concentrations of generic lopinavir/ritonavir in HIV
type-1-infected individuals.
van der Lugt J, Lange J, Avihingsanon A, et a
Antivir Ther.
2009;14(7):1001-4
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Factors influencing lopinavir and atazanavir plasma
concentration.
Stöhr W, Back D, Dunn D,
et al
J Antimicrob Chemother.
2009 Nov 6.
Abstract |
Association between ABCC2 polymorphism and lopinavir accumulation
in peripheral blood
mononuclear cells of HIV-infected patients.
Elens L, Yombi JC,
Lison D, et al
Pharmacogenomics.
2009 Oct;10(10):1589-97
Abstract |
Lopinavir co-induces insulin resistance and ER stress in human
adipocytes.
Djedaini M, Peraldi P, Drici MD,
et al
Biochem Biophys Res Commun.
2009 Jun 4
Abstract |
Binding of Lopinavir to HumanI {alpha}1-Acid Glycoprotein and
Serum Albumin.
Gulati A, Boudinot D, Gerk PM.
Drug Metab Dispos. 2009 May 13.
Abstract |
Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors
Lopinavir and Ritonavir.
Degoey DA, Grampovnik DJ, Flosi WJ, et al
J Med Chem. 2009 Apr 6.
Abstract
|
|
| |
In vitro hypersusceptibility of human
immunodeficiency virus type 1 subtype C
protease to lopinavir.
Gonzalez LM, Brindeiro RM, Tarin M, et al
Antimicrob Agents Chemother. 2003 Sep;47(9):2817-22.
Abstract
|
| |
In vitro antiviral interaction of lopinavir with
other protease inhibitors.
Molla A, Mo H, Vasavanonda S, Han L
Antimicrob Agents Chemother 2002 Jul;46(7):2249-53
Abstract
|
| |
X-ray crystallographic
structure of ABT-378 (Lopinavir) bound to HIV-1 protease.
Stoll V, Qin W, Stewart KD,
Jakob C, et al
Bioorg Med Chem 2002 Aug;10(8):2803-6
Abstract |
| |
|
| |
FULL-TEXT ARTICLE
In
vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison
and metabolite identification.
Kumar GN, Jayanti V,
Lee RD, et al.
Drug Metab Dispos
1999 Jan;27(1):86-91
Paper |
| |
|
| |
Human
serum attenuates the activity of protease inhibitors toward wild-type
and
mutant human immunodeficiency virus
Molla A,
Vasavanonda S, Kumar G, Sham HL, et al.
Virology
1998 Oct 25;250(2):255-62
Abstract |
| |
|
| |
FULL-TEXT ARTICLE
In
vitro selection and characterization of human immunodeficiency virus
type 1
variants with increased resistance to ABT-378, a novel protease inhibitor.
Carrillo A, Stewart KD, Sham HL, et al.
J Virol 1998 Sep;72(9):7532-41
Paper |
| |
Human Immunodeficiency Virus Type 1 Genotypic and
Pharmacokinetic
Determinants of the Virological Response to
Lopinavir-Ritonavir-Containing
Therapy in Protease
Inhibitor-Experienced Patients.
Masquelier B, Breilh D, Neau D, et al.
Antimicrob Agents Chemother 2002 Sep;46(9):2926-2932
Abstract
Pharmacokinetics of amprenavir and lopinavir in combination with
nevirapine
in highly pretreated HIV-infected patients.
Fătkenheuer G, Römer K, Kamps
R, et al
AIDS, 2001:Vol 15, No 17 2334-2355
Abstract
ABT 378/r: a novel inhibitor of HIV-1 protease in
haemodialysis.
Izzedine H, Launay-Vacher V, Legrand M, et al.
AIDS 2001 Mar 30;15(5):662-4
Abstract
FULL-TEXT ARTICLE
Potent
inhibition of the cytochrome P-450 3A-mediated human liver
microsomal
metabolism
of a novel HIV protease inhibitor by ritonavir:
A positive drug-drug
interaction.
Kumar GN, Dykstra J, Roberts EM, Jayanti
VK, Hickman D, et al.
Drug Metab Dispos 1999 Aug;27(8):902-8
Paper
FULL-TEXT ARTICLE
ABT-378,
a highly potent inhibitor of the human immunodeficiency virus
protease.
Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al
Antimicrob Agents
Chemother 1998 Dec;42(12):3218-24
Paper
FULL-TEXT ARTICLE
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency
virus protease by coadministration with ritonavir.
Kempf DJ, Marsh KC, Kumar G, et al;
Antimicrob Agents Chemother
1997 Mar;41(3):654-60
Paper
|
|
|
KLS
Main Page
Main
New/Newsworthy
